Clinical trials
Observational Peripheral Arterial Disease trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 2 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 8 |
| Completed | 7 |
| Recruiting | 5 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shanghai Zhongshan Hospital | 3 |
| First Affiliated Hospital Xi'an Jiaotong University | 2 |
| First Affiliated Hospital of Zhejiang University | 2 |
| Fudan University | 2 |
| Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology | 2 |
| Xuanwu Hospital, Beijing | 2 |
| Acotec Scientific Co., Ltd | 1 |
| Bayer | 1 |
| Beijing Northland Biotech. Co., Ltd. | 1 |
| Fangge Deng | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peripheral Arterial Disease | 26 |
| Chronic Limb-Threatening Ischemia | 4 |
| Calcinosis | 2 |
| Arterial Occlusive Diseases | 1 |
| Arteriosclerosis | 1 |
| Arteriosclerosis Obliterans | 1 |
| Coronary Artery Disease | 1 |
| Diabetic Foot | 1 |
| Kinesiophobia | 1 |
| Sarcopenia | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.